scispace - formally typeset
Search or ask a question

Showing papers by "Gabriel Etienne published in 2009"

Journal Article•DOI•
Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

[...]

Francois-Xavier Mahon, Delphine Rea, François Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet1, Gabriel Etienne, Emilie Aton, Josy Reiffers, Philippe Rousselot •
Paris Descartes University1
20 Nov 2009-Blood
TL;DR: It is confirmed that CMR can be sustained after discontinuation of imatinib with a long follow-up, particularly in male patients and in pts with cytotoxic NK cells in their peripheral blood.

34 citations

Journal Article•DOI•
Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.

[...]

Delphine Rea, Gabriel Etienne, Selim Corm, Pascale Cony-Makhoul, Martine Gardembas, Laurence Legros, V. Dubruille, Sandrine Hayette, Mahon Fx, J M Cayuela, F. E. Nicolini 
26 Feb 2009-Leukemia
TL;DR: Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
Abstract: Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

26 citations

Journal Article•DOI•
Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

[...]

Franck E. Nicolini, Gabriel Etienne, Dominique Bordessoule1, Denis Caillot, Coralie Belanger2, Jean-Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Agnès Guerci-Bresler, Viviane Dubruille, Thierry Lamy, Françoise Huguet, Philippe Rousselot, Michel Tulliez, Jean-Yves Cahn, Martine Gardembas-Pain, Laurence Legros, Frédéric Maloisel, Delphine Rea, Hyacinthe Johnson-Ansah, Pascal Lenain, Alain Delmer, Marc G. Berger, Tomasz Szczudlo2, Jim Wang2, Mei Sheng Duh3, François Guilhot4 •
ALFA1, Novartis2, Analysis Group3, French Institute of Health and Medical Research4
20 Nov 2009-Blood
TL;DR: Overall major cytogenetic response (MCyR) and complete hematologic response (CHR) rates were both 54%, which are higher than those observed in the overall ENACT CML-CP cohort at 45% and 43%, respectively.

3 citations

Patent•
Use of Defensin Alpha 1 and/or Defensin Alpha 4, as a Marker for Predicting Treatment Response and/or a Relapse in a Patient Suffering form Chronic Myeloid Leukemia

[...]

Béatrice Turcq1, Gabriel Etienne1, Maryse Dupouy1, François-Xavier Mahon1, Bertrand Garbay1, Patricia Costaglioli1 •
Centre national de la recherche scientifique1
17 Jul 2009
TL;DR: In this article, the authors used defensin α1 and α4 as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.
Abstract: The present invention pertains to the use of defensin α1 and/or defensin α4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.